Approximately 20% of individuals with metabolic disorders, including hypertriglyceridemia, type 2 diabetes, and obesity, exhibit discordance between apoB and LDL-C levels, underscoring the limitations of LDL-C-based risk assessment (Glavinovic et al., 2022). The gene discussed is APOB; the disease is hypertriglyceridemia.